Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study

Table 5 Comparison of cumulative incidence of predominant progression sites between one extranodal disease in the breast and multiple extranodal disease group according to suggested criteria

	Disease classification	No.	1-year	3-year	5-year	P value
LNs only	OED	1	2.7 ± 2.7	2.7 ± 2.7	2.7 ± 2.7	0.062
	MED	2	7.7 ± 7.4	10.2 ± 8.2	10.2 ± 8.2
Breast (±LNs, ±CNS)	OED	6	7.8 ± 4.3	11.9 ± 5.8	16.6 ± 7.1	0.902
	MED	2	13.7 ± 9.2	13.7 ± 9.2	13.7 ± 9.2
CNS (±LNs, ± other extranodal diseases, but not LNs only and	OED	4	5.5 ± 3.8	8.7 ± 4.8	12.3 ± 8.5	0.411
breast)	MED	2	12.5 ± 8.3	12.5 ± 8.3	12.5 ± 8.3
Extranodal diseases (±LNs, ≥2 or other than	OED	3	2.9 ± 2.8	9.7 ± 5.4	9.7 ± 5.4	0.001
breast and CNS)	MED	6	38.7 ± 14.2	49.0 ± 15.1	49.0 ± 15.1

Values are expressed as cumulative incidence (%) ± standard error unless stated otherwise. Abbreviations: OED, one extranodal disease in the breast; MED, multiple extranodal disease; LNs, lymph nodes; CNS, central nervous system.

ISSN: 1471-2407